Leading Ophthalmologist Prof. David Goldblum MD, Joins Ophthalmic Sciences Board of Directors
​Tel-Aviv, Tuesday, March 2, 2021
Ophthalmic Sciences, the eyecare company and inventor of the IOPerfect™ intraocular pressure (IOP) tracking product, is honored to announce the joining of Prof. Dr. Med. David Goldblum to its Board.
Prof. Goldblum is a professor of ophthalmology at the university of Basel, Switzerland and conducts research in ophthalmology with an emphasis on pharmaceutical and medical device clinical trials, taking part in over one hundred published peer reviewed articles. In addition to his academic roles Prof. Goldblum is the Chief Medical Officer at the Pallas Clinics, the largest swiss eye clinic.
An ophthalmic surgeon specializing in glaucoma, oculoplasty, cornea and ocular pharmacology, Prof. Goldblum brings to the Ophthalmic Sciences Board of Directors meaningful professional, clinical and market expertise that is of significant value as the company enters the clinical and early commercial phases. Upon assuming his position Prof. Goldblum said “I look forward to become part of this exciting new technology and help to bring it to the market”.
Mr. Talor Sachs, the company’s Chairman noted on this occasion “as Ophthalmic Sciences is moving ahead in its clinical studies and preparing for commercialization of its groundbreaking solution, it is essential to connect to key opinion leaders with a deep knowledge and understanding of the glaucoma market. Their input on trends, unmet needs, solutions, pricing and regulation is valuable to the company and Prof. Goldblum is a world-renowned leader in this space. We are very grateful for his contribution”, while the company’s CEO, Mr. Ariel Weinstein added “Prof. Goldblum is a welcome addition to our team, a move that should increase our success likelihood. I look forward to working alongside David”.

The company has initiated a pilot study of the IOPerfect™ in January 2021 and plans to initiate its pivotal study as well as development of its eyecare tele-diagnostics suite product upon completion of its post-seed investment subscription.

About Ophthalmic Sciences:
Ophthalmic Sciences, a privately owned company established in 2019, is dedicated to harnessing AI-based image processing technology to address unmet needs in eyecare with a particular focus on tele-diagnosis. Ophthalmic Sciences operates within eHealth Ventures, a prominent digital health venture fund and incubator.

For more information contact ariel@op-sci.com.

About eHealth Ventures:
eHealth Ventures is the leading early-stage Digital Health investor (VC and Incubator) in Israel and a partnership of multinational medical organizations, industry leaders and financial investors including Maccabi – Israel’s leading HMO, Amgen, Medison Ventures, SCI and others.

For more information contact ophir@ehv.health

Ophthalmic Sciences, the eyecare company and inventor of the IOPerfect™ intraocular pressure (IOP) tracking product, is honored to announce the joining of Prof. Dr. Med. David Goldblum to its Board.

We move fast and push our companies to move faster.
Timing is everything - we get it.
For all news items
eHealth Ventures by Numbers:
Portfolio Companies
Companies Reviewed
Years of experience for 4 principles
Fair Value Appreciation on Portfolio
Partners & Collaborators